Compare Pfizer Inc (PFE) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Williams Companies Inc — how do they compare? Pfizer Inc trades at $27.78 (market cap $159.59B), while Williams Companies Inc trades at $72.43 (market cap $87.41B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Williams Companies Inc for 58 Days on average.
| PFE | WMB | |
|---|---|---|
Market Cap | $159.59B | $87.41B |
Volume | 30,937,010 | 5,173,332 |
Sector | Health | Energy |
52-Week High | $29.02 | $79.40 |
52-Week Low | $23.67 | $56.51 |
Typical Hold Time | 158 Days | 58 Days |
Enterprise Value | $211.09B | $118.03B |
Dividend Yield | 6.14% | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Williams Companies (WMB) trades at $72.34, down 0.07% with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 25.18% net income margin and 24.02% ROE, supported by stable cash flows from operations of $5.90B. Recent earnings show mixed results with Q1 2026 beating expectations while Q2 2026 slightly missed. The company benefits from growing natural gas demand driven by AI data center expansion and maintains a strategic position in midstream energy infrastructure.
WMB presents a compelling investment case with 79% analyst buy ratings and $87.27 consensus price target offering 21% upside. Key opportunities include dividend growth strategy and exposure to AI-powered energy demand, while risks involve energy market volatility and high debt levels of $24.74B long-term debt. The stock's valuation at 28.47 P/E appears justified by strong profitability and growth prospects in natural gas infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
